Raymond Sanchez

Biography

 As Senior Vice President of Global Clinical Development, at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), I have responsibility for overseeing all development activities across the therapeutic areas. I joined Otsuka in 2007 to lead the ABILIFY® (aripiprazole) life cycle management programs. I also led the ABILIFY MAINTENA® (aripiprazole) program that received FDA approval in February 2013, as well as a subsequent approval for acute schizophrenia. Since then, I have served as co-lead for the clinical development and submission of the NDA for REXULTI® (brexpiprazole) that received FDA approval in July 2015. In addition, I have managed the clinical development efforts for the treatment of Tourette’s syndrome with ABILIFY®, and have worked closely with OPDC and other Otsuka colleagues to achieve significant advances in the life cycle development of ABILIFY® (aripiprazole) and other CNS programs. Prior to joining Otsuka, I worked at Bristol-Myers Squibb (BMS) as Group Director, Neuroscience Medical, based in Wallingford, Connecticut, and then in Paris, France, where I was the ABILIFY® (aripiprazole) Medical Lead for Europe. I received an A.B. degree from the Weinberg College of Arts and Sciences at Northwestern University and an M.D. from the Feinberg School of Medicine at Northwestern University and trained in psychiatry at the Yale School of Medicine.

Research Interest

At Otsuka, we are committed to drug discovery and the development of novel therapies to address unmet needs. My peers and I have dedicated our careers to bringing new treatment options to patients and practitioners. We are driven by the opportunities to explore new therapeutic mechanisms, develop novel clinical trial designs, as well as leverage technology to confront the ongoing challenges in pharmaceutical development and advance medical research tailored to the development and availability of the best therapies to treat illnesses